Keywords: USA, FDA, Orlistat, Xenical, Alli, Roche, GlaxoSmithKline, Liver injury
US FDA warns of rare cases of liver injury with use of obesity drugs Xenical and Alli
Article | 27 May 2010
The US Food and Drug Administration yesterday advised consumers and health care professionals about potential rare occurrences of severe liver ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
